Clinical trials
CML, Chronic Phase clinical trials
Below are recruiting cml, chronic phase clinical trials, each written for real people, not researchers. We’re tracking 46 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07549516Recruiting
Asciminib for Philadelphia chromosome-positive CML in chronic phase
This study tests how well asciminib works and how safe it is for people with a type of blood cancer called chronic myeloid leukemia (CML). It helps see if asciminib is a good option compared to other standard treatments.
Baden-Baden, Baden-WurttembergAges 18–100 - NCT03263572RecruitingPhase 2
Study medicines for Philadelphia-positive ALL or relapsed leukemia
This Phase 2 trial tests a combination of medicines to treat Philadelphia chromosome–positive (Ph-positive) or BCR-ABL–positive acute lymphoblastic leukemia (ALL), including cases that have come back or did not respond. It may help by targeting specific leukemia signals while also aiming to improve disease control.
Houston, TexasAges 18 years+ - NCT06082804Recruiting
Nurse-led management for chronic myeloid leukemia
This trial tests whether having a specially trained nurse manage your care can improve outcomes for people with chronic myeloid leukemia (CML) who take oral medication. It may be a good fit if you are starting or changing oral therapy.
AvignonAges 18 years+ - NCT07302776RecruitingPhase 1
Stopping immune suppression after stem cell transplant
This trial tests whether it's safe to stop one type of anti-rejection medication (tacrolimus) earlier than usual after a stem cell transplant from a matched donor. If you qualify, you may be able to reduce your long-term medication burden.
Palo Alto, CaliforniaAges 18–80 - NCT02889003RecruitingPhase 2
Second attempt to stop treatment after pioglitazone in CML
This trial tests if a short course of pioglitazone (a diabetes drug) before stopping your TKI therapy can help you stay in remission longer. It is for people with chronic myeloid leukemia (CML) who have already lost their remission after a first or later attempt to stop TKI treatment.
Le ChesnayAges 18 years+ - NCT07375355Recruiting
A study of Scemblix for newly diagnosed chronic myeloid leukemia in China
This study looks at how well the medicine Scemblix (asciminib) works for people in China who have just been diagnosed with a certain type of leukemia (chronic myeloid leukemia in chronic phase). It aims to see if starting this treatment soon after diagnosis is effective and safe.
Wuhan, HubeiAges 18–99 - NCT06684964Recruiting
Real-world study of asciminib for chronic CML in Saudi Arabia
This study is watching how well asciminib (Scemblix) works in real life for people with chronic-phase CML in Saudi Arabia. If you've already tried two or more targeted therapies (TKIs) and recently started asciminib, this study may help doctors understand more about its effectiveness and side effects.
DammamAges 18–99 - NCT07651878RecruitingPhase 1
Vididencel immunotherapy for chronic myeloid leukemia with minimal residual disease
This study tests whether an experimental immune therapy called vididencel can help patients with chronic myeloid leukemia (CML) who have responded partially to standard tyrosine kinase inhibitor (TKI) drugs. The goal is to see if this therapy can further reduce the cancer cells remaining in their body.
BergenAges 18 years+ - NCT06802315RecruitingPhase 2
Radiation therapy before stem cell transplant for high-risk blood cancers
This trial tests a precise type of radiation called intensity modulated total marrow irradiation before a stem cell transplant. It aims to destroy cancer cells while reducing side effects for patients with high-risk leukemia or myelodysplastic syndrome.
Chicago, IllinoisAges 18–65 - NCT03630991RecruitingPhase 1
Calcium chelator medicine for AML or MDS during chemotherapy
This Phase 1 study tests whether edetate calcium disodium (also called succimer) can be safely given to people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) while they are on chemotherapy. The goal is to learn the safest dose and whether it has signs of helping the blood cancer respond to treatment.
Houston, TexasAges 1 year+ - NCT07354074RecruitingPhase 2
Study of asciminib for children with Ph+ CML
This trial tests an oral medication called asciminib in children and teens with a type of leukemia called Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It aims to see if the drug is safe and effective for patients who are newly diagnosed or whose current treatment has stopped working or caused side effects.
New Brunswick, New JerseyAges 1–18 - NCT03595917RecruitingPhase 1
New and hard-to-treat BCR-ABL leukemia drugs plus prednisone and blinatumomab
This Phase 1 study tests a combination of targeted cancer drugs with prednisone and blinatumomab in people with BCR-ABL–positive B-cell leukemia (B-ALL), or chronic myeloid leukemia (CML) in lymphoid blast crisis. It may help by attacking leukemia cells through multiple pathways, especially when standard intensive chemotherapy is not suitable.
Chicago, IllinoisAges 18 years+ - NCT03589729RecruitingPhase 2
Dexrazoxane to help protect the heart during blood-cancer chemo
This Phase 2 study tests dexrazoxane, a heart-protecting medicine, to reduce heart side effects from chemotherapy in people with certain blood cancers. If you qualify, you would receive dexrazoxane along with chemotherapy, and the team will monitor your heart function closely.
Houston, TexasAges 12 years+ - NCT00816114Recruiting
Chart review for CML patients previously treated with certain pills
This study reviews existing medical records of people with chronic myelogenous leukemia (CML) who were treated with specific FDA-approved targeted tablets (tyrosine kinase inhibitors) at MD Anderson but not on an MD Anderson clinical trial. It may help the hospital understand how these medicines are used in real-world care.
Houston, TexasAges Any age - NCT04260022RecruitingPhase 1
Drug study for hard-to-treat CML or Ph+ ALL
This Phase 1 study tests HQP1351 for people with CML or Ph+ ALL that has not responded well to standard targeted pills (TKIs), or those who could not tolerate them. It’s designed to see whether the treatment can work and how safe it is for this difficult-to-treat group.
Birmingham, AlabamaAges 18 years+ - NCT05682924Recruiting
Study blood vessel function in CML patients on bosutinib
This study looks at how well your blood vessels work (“vasoregulation”) in people with chronic myeloid leukemia (CML) while taking bosutinib. The goal is to understand vascular changes and how they relate to treatment in CML.
MoscowAges 40–60 - NCT06088888RecruitingPhase 1
TGRX-678 for CML that hasn't responded to other treatments
This study tests a new daily pill called TGRX-678 for people with chronic-phase CML who have not responded well to or cannot tolerate other CML treatments. It aims to see if the drug is safe and if it can help control the leukemia.
Houston, TexasAges 18 years+ - NCT05605379Recruiting
Study of how children with CML respond to first TKI treatment
This trial looks at how well children with chronic myeloid leukemia (CML) respond to standard “TKI” tablets when treatment starts. It uses genetic test results from diagnosis (DNA/RNA) to understand which children respond better and why.
BordeauxAges 6–18 - NCT06401603RecruitingPhase 1
Study of three drugs for advanced CML and Ph+ AML
This trial tests a combination of three drugs (decitabine, lisaftoclax, and olverembatinib) for people with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute myeloid leukemia who have not responded to or could not tolerate previous treatments.
Houston, TexasAges 18 years+ - NCT03533816RecruitingPhase 1
Gamma delta T-cell infusion after stem cell transplant
This early-phase study tests giving a special immune-cell treatment after an allogeneic (donor) stem cell transplant, plus a medication given after transplant to help the new immune system work better. It may help prevent or treat cancer returning after transplant.
Westwood, KansasAges 18–65 - NCT05365035RecruitingPhase 2
Phase 2 trial for high-risk blood cancers with timed chemo
This study tests a mix of medicines (cladribine, low-dose cytarabine, and venetoclax) alternated with azacitidine and venetoclax to treat higher-risk CMML or MDS after prior treatment or when standard treatment may not work well. It may help by improving blood counts and controlling the disease.
Houston, TexasAges 18 years+ - NCT05092451RecruitingPhase 1/Phase 2
CD70-targeting NK cell therapy for blood cancer relapse
This study tests an immune therapy made from cord blood “NK cells” that are engineered to attack cells with a marker called CD70. It’s given after chemotherapy that reduces your blood and immune system, aiming to treat relapse or refractory (not responding) blood cancers.
Houston, TexasAges 12–80
Hear when a new CML, Chronic Phase trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cml, chronic phase?
- Yes. Clin2 currently lists 46 recruiting cml, chronic phase studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cml, chronic phase trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cml, chronic phase trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.